Sichan Li
Impact in
- Geriatrics and Gerontology top 10%
- Sirtuins and Resveratrol in Medicine
-
- Antibiotics Pharmacokinetics and Efficacy
Papers in
-
- Antibiotics Pharmacokinetics and Efficacy 7
-
- Neonatal Health and Biochemistry 2
- Pharmacological Effects and Toxicity Studies 2
- Pharmaceutical studies and practices 2
- Co-authors
- Qinglong Guo (2 shared papers)Libin Wei (1 shared paper)Yuening Sun (1 shared paper)Jingyue Yao (1 shared paper)Jian Liu (1 shared paper)Jubo Wang (1 shared paper)Yongjian Guo (1 shared paper)Ye Xu (1 shared paper)
- Journals
- Frontiers in Pharmacology (5 papers)Pharmaceutics (2 papers)The Journal of Clinical Pharmacology (2 papers)Epilepsy & Behavior (1 paper)Epilepsia (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Sichan Li
19 papers receiving 276 citations
Sichan Li's Hit Papers
Peers
Comparison fields: 5 of 65
- Geriatrics and Gerontology 20
- Pharmacology 53
- Epidemiology 85
- Applied Microbiology and Biotechnology 5
- Physiology 12
Countries citing papers authored by Sichan Li
This map shows the geographic impact of Sichan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sichan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sichan Li more than expected).
Fields of papers citing papers by Sichan Li
This network shows the impact of papers produced by Sichan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sichan Li. The network helps show where Sichan Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Sichan Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma Hit paper breakdown → | 2021 | 172 |
| 2 | 2019 | 24 | |
| 3 | 2020 | 19 | |
| 4 | 2023 | 11 | |
| 5 | 2021 | 10 | |
| 6 | 2022 | 7 | |
| 7 | 2022 | 7 | |
| 8 | 2020 | 5 | |
| 9 | 2022 | 5 | |
| 10 | 2022 | 4 | |
| 11 | 2024 | 3 | |
| 12 | 2024 | 2 | |
| 13 | 2024 | 2 | |
| 14 | 2022 | 2 | |
| 15 | 2020 | 1 | |
| 16 | 2024 | 1 | |
| 17 | 2023 | 1 | |
| 18 | 2019 | 1 | |
| 19 | 2025 | 1 |
About Sichan Li
Sichan Li is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health, Epidemiology, Infectious Diseases and Molecular Biology, having authored 19 papers that have together received 278 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (7 papers), Neonatal Health and Biochemistry (2 papers), Antibiotic Resistance in Bacteria (2 papers), Epilepsy research and treatment (2 papers), Antimicrobial Resistance in Staphylococcus (2 papers), Pharmacological Effects and Toxicity Studies (2 papers), Pharmaceutical studies and practices (2 papers) and Antifungal resistance and susceptibility (1 paper). The work is most often cited by research in Geriatrics and Gerontology (20 citations), Pharmacology (53 citations), Epidemiology (85 citations), Applied Microbiology and Biotechnology (5 citations) and Physiology (12 citations). Sichan Li has collaborated with scholars based in China and United States. Frequent co-authors include Qinglong Guo, Libin Wei, Yuening Sun, Jingyue Yao, Jian Liu, Jubo Wang, Yongjian Guo, Ye Xu, Qi Ye and Long Zhang. Their work appears in journals such as Frontiers in Pharmacology, Pharmaceutics, The Journal of Clinical Pharmacology, Epilepsy & Behavior and Epilepsia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.